Performance Study of a Non-invasive Glucose Monitoring Device Prototype

Diabetes Mellitus Clinical Trial

Official title:

Performance Study of a Non-invasive Glucose Monitoring Device Prototype

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03519841
• Other study ID #: RSP-13
• Status: Completed
• Phase: N/A
• Start date: April 13, 2018
• Est. completion date: October 8, 2018

Study information

• Verified date: October 2020
• Source: RSP Systems A/S
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This clinical study has been launched to collect spectral Raman data paired with validated glucose reference values in private homes of subjects.

Description:

Protocol consists of two parts:

Part A) Subjects will collect spectral Raman data on device every 15 minutes for 10 hours a day for five days. The five days will be distributed within a timeframe of ten days. A Flash Glucose Monitor will be used as a comparator. In addition to this, four daily capillary Blood Glucose readings will be collected.

Part B) Subjects will perform four daily measuring sessions in which optical Raman readings are paired with capillary Blood Glucose comparator. Measuring sessions are performed in subjects' own home while maintaining usual diabetes management routines. Subjects will collect data for 30 days during a 60 days' period.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 6
• Est. completion date: October 8, 2018
• Est. primary completion date: October 8, 2018
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Male and female subjects 18 years of age or older

• Diabetic patients (all types), insulin requiring

• Skin phototype 1-4

Exclusion Criteria:

• For female participants: Pregnancy or subject is attempting to conceive or not willing and able to practice birth control during the study duration

• For female participants: Breastfeeding

• Subjects not able to understand and read Danish

• In Investigator's opinion, subject is not able to follow instructions as specified in the protocol

• Rejection by optical screenings

• Participants not able to hold hand/arm steadily (including tremors and Parkinson's Disease)

• Diagnosed with reduced circulation

• Extensive skin changes, tattoos or diseases on probe application site

• Known allergy to medical grade alcohol

• Known allergy to adhesives, applicable to subjects in RSP-13-01

• Systemic or topical administration of glucocorticoids for the past 7 days

• Subjects undergoing dialysis treatment

• Medical history or any condition that may, in the opinion of the Investigator, compromise the subject's ability to participate

• Concomitant medical condition which could present a risk to the safety or welfare of the subject or study staff.

• Participants currently enrolled in another study

Related Conditions & MeSH terms

• Diabetes Mellitus

Intervention

Device:
• P0.1
Investigational Medical Device collecting spectral Raman data from tissue.

Locations

Country	Name	City	State
Denmark	Steno Diabetes Center Odense	Odense

Sponsors (1)

Lead Sponsor	Collaborator
RSP Systems A/S

Country where clinical trial is conducted

Denmark, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Generation and validation of predictive models by ISUP and MARD measures	Optical glucose data will be collected together with paired reference values (BGM and FGM, Protocol 1 and BGM, Subprotocol 2).; For subprotocol 1, measurements will be collected every 15 minutes for 10 hours a day for 5 days distributed over a period of 10 days.; For subprotocol 2, four daily measurements will be collected while subject is maintaining normal routines. Data will be collected for 30 days distributed over a period of 60 days.; Optical glucose readings will be masked to the subjects.; Collected data will be used to generate individual calibration models capable of predicting tissue glucose. Models will be validated on independent data sets using MARD and ISUP measures.	6 months
Secondary	Safety evaluation: paucity of adverse events	Safety will be evaluated in a descriptive manner by the paucity of adverse events	6 months